What Anagenex does

Anagenex is a privately held biotechnology company founded in 2019 and headquartered in Lexington, Massachusetts, operating an ML-driven drug discovery platform focused on small molecule therapeutics against difficult targets. The company's core technology pairs large-scale experimental data generation with machine learning models, creating an integrated wet-lab-and-compute loop that the company describes as a novel method architecture distinguishing it from purely computational or purely empirical drug discovery approaches. Use of Series A proceeds explicitly targets both expansion of the data-generating platform and advancement of new drug programs, indicating the company is building internal pipeline assets alongside its platform offering.

Anagenex pursues a B2B go-to-market motion targeting pharmaceutical companies through drug discovery partnerships and platform licensing arrangements. Commercial terms are not publicly disclosed, and pricing is negotiated deal-by-deal. The company is supported by a high-quality investor syndicate including Catalio Capital Management (Series A lead), Lux Capital, Khosla Ventures, Air Street Capital, Menlo Ventures, Obvious Ventures, and Expeditions, with $37.2 million in disclosed funding across a January 2020 round and a June 2022 Series A. Leadership comprises CEO Nicolas Tilmans and CTO Adrian Schreyer; the company maintains a headcount in the 11–50 range. No named customers, revenue figures, or commercial milestones are disclosed in the available source material, consistent with an early-stage platform company pre-commercial scale or in the early stages of partnership-based monetization.

Name

Anagenex

Website

https://anagenex.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Anagenex is a privately held Lexington, Massachusetts biotech using a proprietary ML-driven, large-scale data-generation platform to discover small molecule drugs against difficult targets, serving pharmaceutical companies through B2B partnerships and licensing deals.

Ownership category

akta.pro rank

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Drug Discovery Platform Services: Revenue generated through drug discovery partnerships and platform licensing arrangements with pharmaceutical companies. The company develops new drug programs using its ML platform and likely commercializes these through partnerships or out-licensing deals with major pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Anagenex operates an ML-driven drug discovery platform that pairs large-scale experimental data generation with machine learning to advance small molecule therapeutic programs against difficult targets. The company develops proprietary datasets and ML models and commercializes its capabilities through drug discovery partnerships and licensing arrangements with pharmaceutical companies rather than selling discrete software products.

Product overview

Anagenex is a biotechnology company that operates a data-generating platform for small molecule drug discovery. The company combines large-scale data generation with machine learning to advance drug programs. Based on the available sources, no specific named products, modules, or sub-brands were identified — the company appears to offer its platform as a unified offering rather than as discrete named products.

Differentiator

Problem solved

Functional benefit

Products and services

• ML-Driven Drug Discovery Platform

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Recursion Pharmaceuticals: Recursion operates a high-throughput experimental biology platform combined with ML to map biology and discover new therapeutics. It is a direct competitor in combining large-scale data generation with ML for drug discovery, with substantially more capital and clinical-stage programs.
• Isomorphic Labs: Isomorphic Labs, an Alphabet subsidiary, applies DeepMind's AI to drug discovery with a focus on difficult targets and pharma partnerships. It is a direct competitor with substantially greater resources and AI capabilities targeting the same difficult-target niche.
• Atomwise: Atomwise applies AI and structure-based design to small molecule drug discovery, partnering with pharma and academic groups. It is a direct peer in the AI small molecule discovery space, particularly for difficult targets.
• Exscientia: Exscientia is an AI-driven drug design company focused on small molecule discovery through computational chemistry and active learning. It directly competes with Anagenex in AI-enabled small molecule drug discovery and pharma partnerships.
• Insitro: Insitro is a machine learning-driven drug discovery company combining high-throughput biology with ML to develop therapeutics. It directly competes with Anagenex in the AI-enabled small molecule and target discovery space serving pharma partners.
• Schrödinger: Schrödinger provides computational chemistry and physics-based simulation platforms used for small molecule drug discovery across pharma. It is a direct competitor with a more mature software platform serving the same pharma R&D customers as Anagenex.

Emerging players

• Lantern Pharma: Lantern Pharma is an AI-driven oncology drug development company using ML to identify responders and repurpose/develop therapeutics. It overlaps with Anagenex in applying AI to small molecule drug discovery, with a narrower therapeutic focus.
• Generate Biomedicines: Generate Biomedicines is an ML-driven generative biology platform creating novel protein therapeutics. It overlaps with Anagenex in applying generative AI to therapeutic discovery, though focused on biologics rather than small molecules.
• BenchSci: BenchSci applies AI to accelerate life science research and preclinical drug discovery, helping scientists select experimental reagents and design experiments. It is an adjacent emerging player that uses ML to improve wet-lab productivity for drug discovery teams.
• Cradle Bio: Cradle applies ML to protein engineering and design. It is a comparable emerging player using ML-driven approaches for therapeutic discovery, though focused on protein design rather than small molecule hit identification.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/anagenex

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anagenex